Scutellarin activates IDH1 to exert antitumor effects in hepatocellular carcinoma progression

Zhao Cui,Caifeng Li,Wei Liu,Mo Sun,Shiwen Deng,Junxian Cao,Hongjun Yang,Peng Chen

DOI: https://doi.org/10.1038/s41419-024-06625-6

2024-04-16

Cell Death and Disease

Abstract:Isochlorate dehydrogenase 1 (IDH1) is an important metabolic enzyme for the production of α-ketoglutarate (α-KG), which has antitumor effects and is considered to have potential antitumor effects. The activation of IDH1 as a pathway for the development of anticancer drugs has not been attempted. We demonstrated that IDH1 can limit glycolysis in hepatocellular carcinoma (HCC) cells to activate the tumor immune microenvironment. In addition, through proteomic microarray analysis, we identified a natural small molecule, scutellarin (Scu), which activates IDH1 and inhibits the growth of HCC cells. By selectively modifying Cys297, Scu promotes IDH1 active dimer formation and increases α-KG production, leading to ubiquitination and degradation of HIF1a. The loss of HIF1a further leads to the inhibition of glycolysis in HCC cells. The activation of IDH1 by Scu can significantly increase the level of α-KG in tumor tissue, downregulate the HIF1a signaling pathway, and activate the tumor immune microenvironment in vivo. This study demonstrated the inhibitory effect of IDH1–α-KG–HIF1a on the growth of HCC cells and evaluated the inhibitory effect of Scu, the first IDH1 small molecule agonist, which provides a reference for cancer immunotherapy involving activated IDH1.

cell biology

What problem does this paper attempt to address?

The problem this paper attempts to address is exploring how the flavonoid compound Scutellarin (Scu) exerts its anti-hepatocellular carcinoma (HCC) effects by activating isocitrate dehydrogenase 1 (IDH1). Specifically, the researchers aim to:

1. **Reveal the mechanism of Scu's activation of IDH1**: Researchers used various experimental techniques, such as protein microarray analysis and molecular dynamics simulations, to investigate how Scu specifically binds to and activates IDH1, particularly the interaction between Scu and the Cys297 site in IDH1.

2. **Evaluate the role of Scu in inhibiting HCC cell growth**: Researchers assessed the impact of Scu on HCC cell growth through in vitro and in vivo experiments, including cell viability, colony formation ability, migration ability, and cell cycle distribution.

3. **Explore the regulatory role of the IDH1-α-KG-HIF1α signaling axis in HCC**: Researchers studied how α-ketoglutarate (α-KG) produced after IDH1 activation downregulates HIF1α expression, thereby inhibiting the glycolysis process in HCC cells and activating the tumor immune microenvironment to achieve anti-tumor effects.

4. **Evaluate the potential of Scu as an IDH1 small molecule agonist**: Researchers validated the potential application value of Scu as the first IDH1 small molecule agonist through a series of experiments, providing a new reference for cancer immunotherapy based on IDH1 activation.

In summary, this paper aims to deeply understand the specific mechanisms by which Scu inhibits HCC progression through IDH1 activation, providing theoretical basis and experimental support for the development of new low-toxicity anti-cancer drugs.